EP2076281A1 - Stabilisierende alkylglykosid-zusammensetzungen und ihre verfahren - Google Patents

Stabilisierende alkylglykosid-zusammensetzungen und ihre verfahren

Info

Publication number
EP2076281A1
EP2076281A1 EP06785482A EP06785482A EP2076281A1 EP 2076281 A1 EP2076281 A1 EP 2076281A1 EP 06785482 A EP06785482 A EP 06785482A EP 06785482 A EP06785482 A EP 06785482A EP 2076281 A1 EP2076281 A1 EP 2076281A1
Authority
EP
European Patent Office
Prior art keywords
composition
peptide
agent
polypeptide
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06785482A
Other languages
English (en)
French (fr)
Other versions
EP2076281A4 (de
Inventor
Edward T. Maggio
Michael R. Ruff
Candace B. Pert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rapid Pharmaceuticals Inc
Aegis Therapeutics LLC
Original Assignee
Rapid Pharmaceuticals Inc
Aegis Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rapid Pharmaceuticals Inc, Aegis Therapeutics LLC filed Critical Rapid Pharmaceuticals Inc
Priority to EP09162179A priority Critical patent/EP2158898A1/de
Priority to EP12165052.7A priority patent/EP2505189B1/de
Priority to EP09161107A priority patent/EP2158920A1/de
Publication of EP2076281A1 publication Critical patent/EP2076281A1/de
Publication of EP2076281A4 publication Critical patent/EP2076281A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP06785482A 2006-06-23 2006-06-23 Stabilisierende alkylglykosid-zusammensetzungen und ihre verfahren Withdrawn EP2076281A4 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP09162179A EP2158898A1 (de) 2006-06-23 2006-06-23 Stabilisierung von Alkylglykosidzusammensetzungen und zugehöriges Verfahren
EP12165052.7A EP2505189B1 (de) 2006-06-23 2006-06-23 Stabilisierung von Alkylglykosidzusammensetzungen und zugehöriges Verfahren
EP09161107A EP2158920A1 (de) 2006-06-23 2006-06-23 Stabilisierung von Alkylglykosidzusammensetzungen und zugehörige Verfahren

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2006/024577 WO2007149096A1 (en) 2006-06-23 2006-06-23 Stabilizing alkylglycoside compositions and methods thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP12165052.7A Division EP2505189B1 (de) 2006-06-23 2006-06-23 Stabilisierung von Alkylglykosidzusammensetzungen und zugehöriges Verfahren
EP09161107.9 Division-Into 2009-05-26

Publications (2)

Publication Number Publication Date
EP2076281A1 true EP2076281A1 (de) 2009-07-08
EP2076281A4 EP2076281A4 (de) 2010-03-03

Family

ID=38833712

Family Applications (4)

Application Number Title Priority Date Filing Date
EP12165052.7A Active EP2505189B1 (de) 2006-06-23 2006-06-23 Stabilisierung von Alkylglykosidzusammensetzungen und zugehöriges Verfahren
EP06785482A Withdrawn EP2076281A4 (de) 2006-06-23 2006-06-23 Stabilisierende alkylglykosid-zusammensetzungen und ihre verfahren
EP09162179A Withdrawn EP2158898A1 (de) 2006-06-23 2006-06-23 Stabilisierung von Alkylglykosidzusammensetzungen und zugehöriges Verfahren
EP09161107A Withdrawn EP2158920A1 (de) 2006-06-23 2006-06-23 Stabilisierung von Alkylglykosidzusammensetzungen und zugehörige Verfahren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP12165052.7A Active EP2505189B1 (de) 2006-06-23 2006-06-23 Stabilisierung von Alkylglykosidzusammensetzungen und zugehöriges Verfahren

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP09162179A Withdrawn EP2158898A1 (de) 2006-06-23 2006-06-23 Stabilisierung von Alkylglykosidzusammensetzungen und zugehöriges Verfahren
EP09161107A Withdrawn EP2158920A1 (de) 2006-06-23 2006-06-23 Stabilisierung von Alkylglykosidzusammensetzungen und zugehörige Verfahren

Country Status (3)

Country Link
EP (4) EP2505189B1 (de)
CA (2) CA2743725A1 (de)
WO (1) WO2007149096A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7582727B1 (en) 2008-07-27 2009-09-01 The Medicinces Company Pharmaceutical formulations of bivalirudin and processes of making the same
US7598343B1 (en) 2008-07-27 2009-10-06 The Medicines Company Pharmaceutical formulations of bivalirudin and processes of making the same
WO2011094632A1 (en) * 2010-01-29 2011-08-04 The Uab Research Foundation Method for administration of insulin and pharmaceutical composition thereof
WO2011139838A2 (en) * 2010-04-28 2011-11-10 Zelos Therapeutics, Inc. Intranasal formulations
SI3586826T1 (sl) * 2010-06-24 2021-09-30 F. Hoffmann-La Roche Ag Sestavki in postopki za stabilizacijo formulacij, ki vsebujejo beljakovine
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
CN109803639B (zh) * 2016-09-29 2024-01-02 艾瑞克有限公司 新制剂
CN115015533A (zh) * 2022-05-31 2022-09-06 江西英大生物技术有限公司 一种氧化低密度脂蛋白测定试剂盒

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3219656A (en) 1963-08-12 1965-11-23 Rohm & Haas Alkylpolyalkoxyalkyl glucosides and process of preparation therefor
US3839318A (en) 1970-09-27 1974-10-01 Rohm & Haas Process for preparation of alkyl glucosides and alkyl oligosaccharides
DK149776C (da) 1984-01-06 1987-04-21 Orion Yhtymae Oy Antibiotisk virksom erytromycinforbindelse og praeparat indeholdende forbindelsen
AT382381B (de) 1984-10-02 1987-02-25 Oesterr Zuckerfab Evidenz Verfahren zur herstellung neuer grenzfl|chenaktiver kohlenhydrat-derivate
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5252318A (en) 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5661130A (en) 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
EP1789075A4 (de) * 2004-08-25 2009-07-01 Uab Research Foundation Absorptionsverbesserer für die arzneimittelverabreichung

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ROCCATANO DANILO ET AL: "Mechanism by which 2,2,2-trifluoroethanol/water mixtures stabilize secondary-structure formation in peptides: a molecular dynamics study." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 17 SEP 2002, vol. 99, no. 19, 17 September 2002 (2002-09-17), pages 12179-12184, XP002563234 ISSN: 0027-8424 *
See also references of WO2007149096A1 *

Also Published As

Publication number Publication date
EP2158898A1 (de) 2010-03-03
WO2007149096A1 (en) 2007-12-27
EP2076281A4 (de) 2010-03-03
CA2743725A1 (en) 2007-12-27
EP2505189B1 (de) 2018-08-08
EP2505189A1 (de) 2012-10-03
CA2714867A1 (en) 2007-12-27
EP2158920A1 (de) 2010-03-03

Similar Documents

Publication Publication Date Title
US7425542B2 (en) Stabilizing alkylglycoside compositions and methods thereof
US7390788B2 (en) Peptide pharmaceutical compositions
US8173594B2 (en) Stabilizing alkylglycoside compositions and methods thereof
US20090326193A1 (en) Stabilizing alkylglycoside compositions and methods thereof
US10046025B2 (en) Stabilizing alkylglycoside compositions and methods thereof
US8084022B2 (en) Stabilizing alkylglycoside compositions and methods thereof
US7998927B2 (en) Stabilizing alkylglycoside compositions and methods thereof
EP2505189B1 (de) Stabilisierung von Alkylglykosidzusammensetzungen und zugehöriges Verfahren
DE4242863A1 (de) Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
WO2000072870A1 (en) Compositions of a-beta peptide and processes for producing same
DK2598160T3 (en) Stabilization of FSH
JP6397984B2 (ja) 乾燥粉末ペプチド医薬
CN115364060A (zh) 一种冻干药物制剂及其用途
WO1992011022A1 (en) Pharmaceutical preparation for pernasal administration

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090120

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/28 20060101ALI20100120BHEP

Ipc: A61K 47/26 20060101ALI20100120BHEP

Ipc: A61K 38/29 20060101ALI20100120BHEP

Ipc: A61K 38/27 20060101ALI20100120BHEP

Ipc: A61K 38/21 20060101ALI20100120BHEP

Ipc: A61K 38/18 20060101ALI20100120BHEP

Ipc: A61K 38/08 20060101ALI20100120BHEP

Ipc: A61K 9/19 20060101AFI20100120BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20100129

17Q First examination report despatched

Effective date: 20100413

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130507